University of Leicester
Browse
1-s2.0-S0085253818308111-main (1).pdf (744.96 kB)

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Download (744.96 kB)
journal contribution
posted on 2019-08-28, 10:27 authored by BH Rovin, DJ Caster, DC Cattran, KL Gibson, JJ Hogan, MJ Moeller, D Roccatello, M Cheung, DC Wheeler, WC Winkelmayer, J Floege, Conference Participants
In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.

Funding

The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Achillion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCentryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma.

History

Citation

Kidney International, 2019, 95 (2), pp. 281-295

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammation

Version

  • VoR (Version of Record)

Published in

Kidney International

Publisher

Elsevier for International Society of Nephrology

eissn

1523-1755

Acceptance date

2018-11-01

Copyright date

2019

Available date

2019-08-28

Publisher DOI

Publisher version

https://www.sciencedirect.com/science/article/pii/S0085253818308111?via=ihub

Notes

SUPPLEMENTARY MATERIAL Table S1. 2012 Kidney Disease: Improving Global Outcomes (KDIGO) glomerulonephritis (GN) guideline recommendations related to minimal change disease, focal segmental glomerulosclerosis (FSGS), steroid-sensitive nephrotic syndrome (SSNS), and steroid-resistant nephrotic syndrome (SRNS): Need to be revisited? Table S2. 2012 Kidney Disease: Improving Global Outcomes (KDIGO) glomerulonephritis (GN) guideline recommendations related to idiopathic membranoproliferative glomerulonephritis: Need to be revisited? Table S3. 2012 Kidney Disease: Improving Global Outcomes (KDIGO) glomerulonephritis (GN) guideline recommendations related to lupus nephritis: Need to be revisited? Table S4. 2012 Kidney Disease: Improving Global Outcomes (KDIGO) glomerulonephritis (GN) guideline recommendations related to antineutrophil cytoplasmic antibody–associated vasculitis (AAV): Need to be revisited? Supplementary material is linked to the online version of the paper at www.kidney-international.org.

Language

en

Administrator link

Usage metrics

    University of Leicester Publications

    Categories

    Keywords

    C3 glomerulopathyKDIGOanti-neutrophil cytoplasmic antibody–associated vasculitisfocal and segmental glomerulosclerosislupus nephritismembranoproliferative glomerulonephritisminimal change diseasemonoclonal gammopathies of renal significance

    Licence

    CC BY-NC-ND 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC